news

We are pleased to announce that the clinical results of our HLA TGS kits developed by U-GEN’s subsidiary TBG (Xiamen), titled "Application of ONT in Ambiguous Results of the HLA-DPB1 Genotyping," have been successfully published in the June 2024 issue (Vol. 26, No. 3) of the Journal of Clinical Transfusion and Laboratory Medicine. The research was conducted by HLA Laboratory, Beijing Red Cross Blood Center. It focuses on analyzing the efficiency, advantages, and…

Great news! TBG (Xiamen) has been selected as a National Reference Laboratory for Human Leukocyte Antigen (HLA) Typing. The company will actively participate in the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 gene typing standardization work organized by the National Institutes for Food and Drug Control. This honor not only affirms TBG (Xiamen)'s expertise in the HLA field but also showcases its leading position in the development of molecular diagnostic reagents. Read More in…

Yearth and Professor, Long Wang in The Third Xiangya Hospital, Central South University, has developed a new urine biopsy-based risk stratification model. This model identifies residual tumors after initial Transurethral Resection of Bladder Tumor (TURBT), avoiding unnecessary re-TURBT. Recently, this study was successfully published in the journal Clinical and Translational Medicine (IF=10.6). Title: Urinary DNA methylation-based risk stratification model to triage patients for repeat transurethral resection of bladder tumours Read More in Chinese

Yearth and the professor, Long Wang in The Third Xiangya Hospital, Central South University, completed the study for auxiliary diagnosis of upper tract urinary carcinoma. The results have been published in Cancers (IF=6.58). Title: Urine Cellular DNA Point Mutation and Methylation for Identifying Upper Tract Urinary Carcinoma Read More in Chinese

Yearth’s service laboratory in Changsha has obtained the newest EQA Certificate of the National Center for Clinical Laboratories (NCCL). Human Leukocyte Antigen (HLA) A, B, C, DQB1 and DRB1 loci using next-generation sequencing (NGS) all pass the testing successfully. Read More in Chinese

Yearth’s service laboratory in Changsha has obtained the newest EQA Certificate of the National Center for Clinical Laboratories (NCCL). Structural chromosome abnormalities, fetal chromosomal aneuploidy in peripheral maternal blood (T21, T18, and T13), Covid-19 test, somatic mutations detection for solid tumor, circulating tumor DNA gene mutation, and so on items all pass the testing successfully. Read More in Chinese

Welcome to visit U-GEN! We are delight that you are here!